Do Invalid HBsAg/anti-HBc/anti-HTLV-I/II ChLIA Results Follow Through to Subsequent Donations?

被引：0
|
作者：
Kiely, N. [1 ]
Kamel, H. [1 ]
Tomasulo, P. A. [1 ]
Roesler, P. [2 ]
机构：
[1] Blood Syst, Scottsdale, AZ USA
[2] Creat Testing Solut, Tempe, AZ USA
来源：
TRANSFUSION | 2011年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：205A / 206A
页数：2
相关论文
共 44 条
  • [41] SURROGATE TESTING OF DONORS FOR NON-A, NON-B HEPATITIS - DO CURRENT ANTI-HBC ASSAYS PROVIDE RESULTS WHICH ARE COMPARABLE TO THOSE OBTAINED PREVIOUSLY
    HOLLINGER, FB
    TROISI, CL
    JOURNAL OF MEDICAL VIROLOGY, 1987, 21 (04) : A45 - A46
  • [42] Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBC positive patients undergoing rituximab-based chemotherapy for non-Hodgkin b cell lymphoma - final results
    Grossi, Glenda
    Loglio, Alessandro
    Vigano, Mauro
    Cappelletti, Mattia
    Goldaniga, Maria C.
    Farina, Lucia
    Rumi, Maria G.
    Corradini, Paolo
    Baldini, Luca
    Colombo, Massimo
    Lampertico, Pietro
    HEPATOLOGY, 2016, 64 : 888A - 888A
  • [43] High prevalence of false-negative anti-HTLV type I/II enzyme-linked immunosorbent assay results in HIV type 1-positive patients
    Zehender, G
    DeMaddalena, C
    Gianotto, M
    Cavalli, B
    Santambrogio, S
    Orso, M
    Moroni, M
    Galli, M
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (13) : 1141 - 1146
  • [44] A phase I/II study of the efficacy and toxicity of humanized anti-tac (HAT, Zenapax®) for the treatment of tac-expressing human lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL):: Interim results.
    Morris, JC
    Janik, JE
    Turner, M
    Lee, C
    Top, L
    Jaffe, ES
    Stetler-Stevenson, M
    Bleesing, JJ
    Fleisher, T
    Waldmann, TA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 : S29 - S29
12345